ASCO 2021 Prostate Cancer

Viewing 1-20 of 90 articles

ASCO 2021: The Variability in Prostate Cancer Treatments and Outcomes Based on Geographic Location and Race

ASCO 2021: Complementary Detection of Genomic Alterations in Metastatic Castration Resistant Prostate Cancer From CheckMate 9KD Through Analyses of Tumor Tissue and Plasma DNA

ASCO 2021: An Open-Label, Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Dose Oral Docetaxel in Metastatic Prostate Cancer Patients Treated with IV Docetaxel

ASCO 2021: Differences in Toxicity and Outcomes: A Race-based Case Study

ASCO 2021: Genomic Disparities Across Gleason Scores

ASCO 2021: Safety and Efficacy of AMG 160, a Half-Life Extended BiTE Immune Therapy Targeting PSMA, and Other Therapies for Metastatic Castration-Resistant Prostate Cancer

ASCO 2021: Race, Ethnicity, and Cancer Disparities: Ending the Genetic Debate

ASCO 2021: SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) plus TAK-700 with ADT plus Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2021: Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)?

ASCO 2021: Association of Increased Intensity of Prostate-Specific Antigen (PSA) Screening in Younger African American Men with Improved Prostate Cancer Outcomes

ASCO 2021: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Radium-223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis

ASCO 2021: Are We Making Progress in Addressing Disparities in Prostate Cancer?

ASCO 2021: VanDAAM Study: A Prospective Validation of the Genomic Classifier to Define High-Metastasis Risk in a Subset of African American Men with Early Localized Prostate Cancer

ASCO 2021: First Results of PEACE-1: A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone And/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ASCO 2021: Single-Lesion PSMA Protein Expression and Response to Lu-177 PSMA Therapy In Patients With Castration-Resistant Prostate Cancer

ASCO 2021: Real-World First-Line Treatment Patterns in Patients with Metastatic Castration-Sensitive Prostate Cancer in a U.S. Health Insurance Database

ASCO 2021: Long-Term Adverse Events (AE) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Receiving Prostate-Specific Membrane Antigen (PSMA)-Based Targeted Radionuclide Therapy (TRT)

ASCO 2021: Differences in the Pattern of and Response to Treatment: Not Just Race

ASCO 2021: Do Our Treatments Drive a New Resistant Mutational Phenotype?

ASCO 2021: The New Avengers in the Treatment of Prostate Cancer

1
2
3
4
5

email news signup